Dr. Gabriel Pardo

EBV is required for the development of multiple sclerosis, but it’s not known how a common virus leads to disease. 3 exciting new papers in @CellCellPress provide major insights into how this may occur:

Six-year safety and efficacy outcomes with first-line ofatumumab in re... sciencedirect.com/science/articl… Exploring longterm effects of early initiation of highly effective treatment as first line in MS; positive data!

Repairing MS: The Quest to Rebuild Myelin New MS Living Well Podcast🎙️Guests: Veronique Miron PhD🇨🇦 @UofT & Rob Glanzman MD 🇺🇸 bit.ly/47BfjJ8 🍏apple.co/3JUhTQz @MSCanOfficial @DrJim4MS @MStranslate @DocforMS @DrJNicholas Sponsor: @TGTherapeutics

#ECTRIMS2025 coming up in Sept. 24-26 in Barcelona. Off to Toronto, Canada in 2026! ⛸️ Advances in #MS🌲#ECTRIMS2026! 🇨🇦 @AlexMuccilli @MSDoc_Freedman @DocforMS @DrJNicholas @Brandon_Beaber @C_OrejaGuevara @KlausSchmierer @J_SastreGarriga @bart_professor @anneke_vdw @ECTRIMS

🚀Boosting Brain Health: Blueprint for MS New MS Living Well Podcast 🎧🚶‍♀️🥗😴🧘‍♀️ bit.ly/3FyR2b0🍏apple.co/4jHbiow @KlausSchmierer @DocforMS @anneke_vdw @C_OrejaGuevara @ahmedzobeidat @bart_professor Sponsor: @TGTherapeutics

Want to learn more about visual involvement in MS? Watch this: Bringing MS Vision Problems Into Focus - Can Do MS. cando-ms.org/resource/bring…

Advocacy in action! Fearless Lea Campbell obtained -again- a Governor’s proclamation making March the #NMOSD month in Oklahoma. #MOGAD #raredisease @guthyjacksonfdn @TheSumairaFDN @OMRF

How can functional, anatomic, and biologic tools optimize treatment and risk mitigation for people with progressive #multiplesclerosis? Read Dr. Pardo's (@DocforMS) review article in our February issue. practicalneurology.com/articles/2025-… @OMRF @mscare @mssociety @AANmember @ACTRIMS @ACPIMPhysicians #MS

Proud to share ongoing work on novel approaches to quantifying #MS impact. @ViewMind_ Eye movement deficits in Multiple Sclerosis: characterizing executive ... sciencedirect.com/science/articl…

@pabear5 @Brandon_Beaber @OMRF @AaronBosterMD @drbarrysinger @MSViewsandNews @WHO Sure! It is because there is no prospective cohort on rituximab followed in a controlled manner started shortly after diagnosis and with close monitoring. What this teaches us is the long term benefits -and problems- of using highly effective therapy early on. We learn!

@DocforMS @Brandon_Beaber @OMRF @AaronBosterMD @drbarrysinger @MSViewsandNews Why not a collaborative work on the effficacy of #rituximab, less expensive than #ocrelizumab. Rituximab is on the 2023 updated @WHO list of essential medicines for #MultipleSclerosis Why do you talk only about ocrelizumab? Can you show please your conflicts of interest?

Happy to share this collaborative work looking at long term results of a high efficacy DMT in early #MS #ocrelizumab ⁦@OMRF⁩ ⁦⁦@AaronBosterMD⁩ ⁦@drbarrysinger⁩ ⁦@Brandon_Beaber⁩ ⁦@MSViewsandNews⁩ neurology.org/doi/10.1212/WN…

Thought-provoking discussion about gaps in MS treatments and the role of microglia and CNS targeting therapies by @DocforMS at #TNSW2025 @Texas_Neuros

So happy to share the day, knowledge, and experiences with 400+ patients and caregivers at Dr. Khatri’s Living Well with #MS and Other Autoimmune Neurological Disorders in Milwaukee. #NMOSD #MOGAD @OMRF

Patient education day #NMOSD #MOGAD with the @guthyjacksonfdn in OKC. Committed to improving care and science of rare diseases

@GavinGiovannoni Farewell from the clinic …not an intelectual/science farewell. Plenty to sort out and happy to learn you will continue to pursue much needed answers. See you on the road!

@okudaMD Healthcare systems in US and globally must use medical providers , medications and infrastructure more rationally and equitably. We need to make an even bigger difference. #waste #healthcare

Have you ever wondered about the magnitude of new/unused disease modifying therapies for multiple sclerosis that may be out there? Retail costs for these specialty medicines are near $100K per year! This is a before and after photo from 2020. Imagine for a minute what we have collected up to present day. Enthusiasm for fixing the problem is low especially when compensation has already occurred along the distribution chain. @davidbalat @patientsrising @ectrims @actrims @mssociety @docforms @DrugChannels @elonmusk

Highlighting our latest work on elucidating mechanisms of disease. Obesity intensifies sex-specific interferon signaling to selectively w... @omrf @drbarrysinger @C_OrejaGuevara @Brandon_Beaber @AaronBosterMD @NerdyNeuroMD sciencedirect.com/science/articl…

MS & The Spinal Cord; New MS Living Well podcast🎙️ Guests: Drs. Cree & De Luca. 80% of people with #MS have spinal cord lesions on MRI. bit.ly/4dsbd68🍎apple.co/3MfHFN3 @KlausSchmierer @C_OrejaGuevara @Brandon_Beaber @themsguide @MustStopMS @DocforMS @jsabatino37

⏰ Counting down the days until I present my research at #ECTRIMS2024. Looking forward to engaging discussions and learning from fellow researchers and practitioners. #MS #msresearch app.sosha.ai/s/1BG5gydj